What happened on the stock market today?

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "The actions closed a week of unprecedented highs with Investors have begun to look forward to the publication of their results next week. Dow Jones Industrial Average (DJINDICES: ^ DJI) and the S & amp; P 500 (SNPINDEX: ^ GSPC) record close, with the sectors of the industry and consumer discretionary leading the way. "Data-reactid =" 16 "> The shares closed a week of record highs with another day of strong growth, as investors start looking for earnings reports next week. Dow Jones Industrial Average (DJINDICES: ^ DJI) and the S & P 500 (SNPINDEX: ^ GSPC) record close, with the sectors of the industry and consumer discretionary leading the way.

Stock Market Today

Data source: Yahoo! Finance.

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "As for individual actions, Illumina (NASDAQ: ILMN) warned of a shortfall, and Novartis (NYSE: NVS) and Amgen (NASDAQ: AMGN) announced the failure of a candidate drug treatment for Alzheimer's disease. "Data-reactid =" 21 "> With regard to individual stocks, Illumina (NASDAQ: ILMN) warned of a shortfall, and Novartis (NYSE: NVS) and Amgen (NASDAQ: AMGN) announced the failure of a candidate drug treatment for Alzheimer's disease.

More

Illumina warns of weak sales

<p class = "canvas-atom web-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Illumina shares plunged 16, 1% after sequencing the published leader gene & nbsp;preliminary results& nbsp; for the second quarter, they announced disappointing sales and lowered their guidance for the year. Illumina said it expects second-quarter revenue would have risen 0.6 percent to $ 835 million, about $ 45 million less than analysts' forecasts. The company has been guiding its revenue growth by 6% over the year, less than half of the 13% to 14% that it has.had already planned. "data-reactid =" 34 "> Illumina shares dipped 16.1% after gene sequencing official released preliminary results for the second quarter, warning of disappointing sales and lower forecasts For the year, the quarterly revenue rose 0.6% to $ 835 million, about $ 45 million lower than analysts expected.

Illumina said that $ 30 million of this shortfall was related to population genomics initiatives, including a delay in concluding a major contract that should be finalized later in the year. About $ 10 million is due to the weakness of the direct-to-consumer market, and $ 10 million to the weakness of the company's low-throughput systems.

<p class = "canvas-atom-canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "The course of the action of Illumina has increased recently, and today's move only brings it back to its level of less than two months ago, but forecasts for the full year imply that second half revenues will be about 200 Millions of dollars in the forecast and investors will have to wait until the earnings report is released on July 29. to understand why & nbsp;a slowdown in growth continues. "data-reactid =" 36 "> Illumina's share price has risen recently and the current move is bringing it back to its level less than two months ago. But the forecast for all year involve a business turnover of about 200 USD for the second half million dollars less than expected, and investors will have to wait for the report on the results of July 29 to understand why the slowdown in growth continues.

Even more bad news for patients with Alzheimer's

The latest failure of a drug to treat Alzheimer's disease was announced yesterday, when Novartis and Amgen announced work stoppage on CNP520, or umibecestat, undergoing late-stage clinical trials. The companies stated that a pivotal phase 2/3 trial was stopped after an assessment revealed a deterioration in cognitive function and that the potential benefits to participants did not outweigh the risk. Novartis shares fell 2.4% and Amgen shares fell 1.7% on news.

The CNP520 has been designed to bind to the amyloid proteins that develop in plaques in the brains of patients with Alzheimer's disease. It was currently being tested in people at high risk of developing the disease based on age and genetics. Novartis and Amgen hoped that the drug would delay or prevent the onset of Alzheimer's disease.

<p class = "canvas-atom-canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "The failure is only the last among several attempts to treat Alzheimer's disease by attacking amyloids. Biogen and Eisai recently & nbsp;threw the sponge& nbsp; on aducanumab, join & nbsp;other busts& nbsp; by Merck, Eli Lilly, and others. The & nbsp;amyloid hypothesis& nbsp; can be dead at this point, and the & nbsp; from BiogenCandidate treatment BAN2401& nbsp; could be the next to fall. "data-reactid =" 40 "> Failure is just one of the latest attempts to treat Alzheimer's disease by amyloid attacks. Biogen and Eisai recently threw the sponge on the aducanumab, joining the other busts of Merck, Eli Lilly, and others. The hypothesis of amyloid may be dead at this stage and Biogen's treatment candidate BAN2401 could be the next to fall.

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "More from The Motley Fool"data-reactid =" 42 ">More from The Motley Fool

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Jim Crumly holds shares of Illumina. The Motley Fool owns shares and recommends BIIB and Illumina. The Motley Fool recommends AMGN. The Motley Fool has a disclosure policy."data-reactid =" 51 ">Jim Crumly holds shares of Illumina. The Motley Fool owns shares and recommends BIIB and Illumina. The Motley Fool recommends AMGN. The Motley Fool has a disclosure policy.